Numerof’s 2026 Global Medical Device Outlook infographic maps the major stakeholders in the medical device ecosystem and what we expect from them in the year ahead. The common thread that connects them all is the increasingly focused drive by public and private payers across the globe to reduce the cost of healthcare. That force is powering growth and making new demands on manufacturers. Device companies that can adapt their strategies and processes to these demands stand to prosper. The global outlook for the industry remains positive, with growth projections ranging from 5-7% CAGR over the next five years, and substantially higher for selected sub-segments. But understanding the way in which the environment is changing and the business implications, is the first step to success in 2026 and the years ahead.

The dual issues of value and cost remain at the top of the list for payers across the globe. Interest in the integration of new technologies (AI/ ML, predictive analytics) is high, driven by the promise of reduced labor costs, faster delivery and reduced cost of care based on early intervention. But payers also want transparency regarding product cost and a compelling data-based value case for purchase. This translates to growing emphasis on evidence of better outcomes and lower costs based on real world evidence.

Regulators are trying to keep up with emerging technology, resulting in evolving standards (e.g. for AI, software, cybersecurity), and varied regulations across global markets. Enforcement, especially in the adverse event reporting universe continues to be a priority, and compliance a pain-point for manufacturers.

Demanding evidence of better outcomes and lower costs, government and private payers will continue to expand value-based contracting, reference pricing, and direct purchasing of devices. Consumers will get more involved in choosing diagnostic tests as they also shop for lower cost, higher quality procedures. Employers and payers will look for ways to accelerate the migration of care to outpatient clinics as a path to lower costs and improved outcomes, creating new opportunities for innovative medical device makers.

In the U.S., centralization of decision-making in consolidated integrated delivery networks (IDNs) will continue to erode the influence of clinicians in buying decisions. Building relationships with influencers within these accounts that enables better positioning will be key to future success.

Given this outlook, what’s next?  We recommend these key action steps:

• Innovate new products/services for select markets and use across the care continuum, including health at home.
• Craft compelling databased economic & clinical value narratives that resonate
  with key stakeholders.
• Redesign commercial and medical models.
• Align R&D, Medical Affairs, Commercial functions.
• Recruit, train talent to engage executive decision makers.
• Elevate business acumen, diagnostic, and influence skills.
• Structure more strategic collaborations with providers/payers.

At Numerof & Associates, we help medical device manufacturers achieve these key action steps for success in today’s evolving healthcare landscape. From competitive strategy and ensuring evidence to demonstrate value to commercial model innovation and implementation, we have solutions. Read more about our perspectives and solutions for the medical device industry and see our case studies.

Need critical insights across the healthcare sector? Check out our 2026 outlook infographics for payers, healthcare delivery, and pharmaceuticals.